Home

Novo Nordisk A/S Common Stock (NVO)

80.15
+3.00 (3.89%)

Novo Nordisk A/S is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals, primarily in the fields of diabetes care and hormone replacement therapy

With a strong emphasis on research and development, the company aims to improve the lives of patients with chronic conditions by providing high-quality medications and medical devices. Novo Nordisk is recognized for its comprehensive approach to diabetes management, including insulin products and modern delivery systems, while also expanding its portfolio to address other serious conditions, such as obesity and rare blood disorders. The company operates in numerous countries, combining expertise in biotechnology with a commitment to sustainability and corporate responsibility.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close77.15
Open79.64
Bid80.60
Ask80.74
Day's Range79.35 - 80.56
52 Week Range73.80 - 148.15
Volume5,985,287
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield1.026 (1.28%)
1 Month Average Volume8,066,495

News & Press Releases

UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspensionbenzinga.com
Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with industry standards.
Via Benzinga · March 17, 2025
Why Hims & Hers Stock Popped on Mondayfool.com
Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock?
Via The Motley Fool · March 17, 2025
3 Unstoppable Stocks You Can Buy Now Without Any Hesitationfool.com
Via The Motley Fool · March 17, 2025
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · March 15, 2025
Why Novo Nordisk Stock Is Falling Todayfool.com
Via The Motley Fool · March 10, 2025
CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participantsbenzinga.com
CVS Weight Management program members achieved 15% average weight loss, with 92% satisfaction and 26% lower GLP-1 medication costs for participating clients.
Via Benzinga · March 14, 2025
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disordersbenzinga.com
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
Via Benzinga · March 14, 2025
The Motley Fool's Market Volatility Toolkitfool.com
Long-Term Perspective and Practical Steps for Uncertain Times
Via The Motley Fool · March 13, 2025
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesitybenzinga.com
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.
Via Benzinga · March 13, 2025
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (NYSENVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).
By Lowey Dannenberg, P.C. · Via GlobeNewswire · March 12, 2025
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Droppedfool.com
Ignore the noise in GLP-1 stocks. Find the best value instead.
Via The Motley Fool · March 12, 2025
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billioninvestors.com
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.
Via Investor's Business Daily · March 12, 2025
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?fool.com
Shutting down an acquisition caught investor attention, but there's more to the story.
Via The Motley Fool · March 11, 2025
Is Eli Lilly Stock a Buy?fool.com
Via The Motley Fool · March 11, 2025
NVO Shareholders Have an Opportunity to Lead the Class Action Against Novo Nordisk A/S – Contact Shareholder Rights Law Firm Robbins LLP for Information
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S (NYSENVO) securities between November 2, 2022 and December 19, 2024. Novo is a healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally.
By Robbins LLP · Via GlobeNewswire · March 11, 2025
The State of Weight Loss Drugsfool.com
Via The Motley Fool · March 10, 2025
Why Hims & Hers Health Stock Just Poppedfool.com
Via The Motley Fool · March 11, 2025
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · March 11, 2025
3 Cold Stocks That Can Bounce Back This Weekfool.com
These three stocks tumbled by at least 20% last week, but they may not be down for long.
Via The Motley Fool · March 10, 2025
Top 3 Health Care Stocks That May Keep You Up At Night In Q1benzinga.com
Via Benzinga · March 11, 2025
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trialbenzinga.com
Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.
Via Benzinga · March 11, 2025
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?fool.com
Via The Motley Fool · March 11, 2025
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.investors.com
Novo Nordisk's experimental obesity drug failed to top Eli Lilly's Zepbound. But there's something else that rattled investors.
Via Investor's Business Daily · March 10, 2025
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.
Via MarketBeat · March 10, 2025
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionrocket-com
Via Benzinga · March 10, 2025